Your session is about to expire
← Back to Search
Study Summary
This trial is testing the effectiveness and safety of a drug called baxdrostat/dapagliflozin in adults over 18 with chronic kidney disease (CKD) and high blood pressure
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 4 trial • 30 Patients • NCT03006471Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the potential risks associated with Baxdrostat/dapagliflozin in terms of patient safety?
"The safety assessment of Baxdrostat/dapagliflozin by our team at Power stands at 3 on the scale, reflecting its Phase 3 trial status with existing efficacy data and robust safety data."
Are there any current openings for participants in this research study?
"Information available on clinicaltrials.gov indicates that recruitment for this particular trial has concluded. Despite initial posting on 3/29/2024 and the latest update made on 2/13/2024, there are currently 1202 other ongoing studies actively seeking participants."
Is the clinical trial open to individuals who are below 45 years of age?
"In this research study, individuals above 18 years of age and below 130 years old are eligible to participate."
At how many distinct locations is this medical trial being administered?
"Currently, patient recruitment is ongoing at 297 sites spread across various cities including Lincoln, Tarzana, and Arvada. Opting for a site close to your residence can help reduce travel burden upon enrollment."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger